Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Cancer Research UK
Novartis
Stanford University
UroGen Pharma Ltd.
Poseida Therapeutics, Inc.
University Health Network, Toronto
University Medical Center Groningen
AO GENERIUM
Syndax Pharmaceuticals
Syndax Pharmaceuticals
University Hospital, Bordeaux
Celldex Therapeutics
Celldex Therapeutics